CFTR corrector 16, identified by its CAS number 1210305-23-9, is a small molecule designed to enhance the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is crucial for chloride ion transport across epithelial cell membranes. This compound is part of a class of therapeutics aimed at correcting misfolded CFTR proteins caused by mutations, particularly the F508del mutation, which is the most common cause of cystic fibrosis. CFTR corrector 16 works by stabilizing the protein's structure, promoting its trafficking to the cell surface, and improving its function. The compound is typically characterized by its molecular structure, which includes specific functional groups that contribute to its biological activity. In preclinical studies, CFTR corrector 16 has shown promise in enhancing chloride transport in cells expressing the mutant CFTR, making it a potential candidate for therapeutic development in cystic fibrosis treatment. Further research is necessary to fully understand its efficacy, safety, and potential side effects in clinical settings.

CFTR corrector 16

1210305-23-9: CFTR corrector 16, identified by its CAS number 1210305-23-9, is a small molecule designed to enhance the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is crucial for chloride ion transport across epithelial cell membranes. This compound is part of a class of therapeutics aimed at correcting misfolded CFTR proteins caused by mutations, particularly the F508del mutation, which is the most common cause of cystic fibrosis. CFTR corrector 16 works by stabilizing the protein's structure, promoting its trafficking to the cell surface, and improving its function. The compound is typically characterized by its molecular structure, which includes specific functional groups that contribute to its biological activity. In preclinical studies, CFTR corrector 16 has shown promise in enhancing chloride transport in cells expressing the mutant CFTR, making it a potential candidate for therapeutic development in cystic fibrosis treatment. Further research is necessary to fully understand its efficacy, safety, and potential side effects in clinical settings.

<p>CFTRcorrector 16 (Compound 39) is a corrector of the cystic fibrosis transmembrane conductance regulator (CFTR), utilized in the research of cystic fibrosis disease.</p>

CAS 1210305-23-9

CFTR corrector 16

CFTR corrector 16

Ref: TM-T200113